Australia's Immutep tops Ordinaries Index on positive trial data for cancer therapy

Immutep

05/06/2023 05:56

** Shares of Immutep Ltd  IMM.AX  rise as much as 21.2% to
A$0.315, their biggest intraday pct gain since May 18
    ** Stock of the clinical-stage biotechnology firm is biggest
gainer in the ASX All Ordinaries index  .AORD 
    ** Co announces positive results for phase-II trial of
eftilagimod alpha (efti), a protein that improves immunity for
cancer treatment
    ** Adds that results are "are very encouraging in a
difficult to treat patient population"
    ** IMM stock at its highest since May 29; more than 4.8 mln
shares change hands vs the 30-day average of 2.5 mln shares
    ** IMM down 4% this year, as of last close, vs a 1.5%
increase in the ASX All Ordinaries index 

    

 (Reporting by Sameer Manekar in Bengaluru)
 ((Sameer.Manekar@thomsonreuters.com; Twitter: https://twitter.com/sameer_manekar))